NAGE logo

NAGE
Niagen Bioscience Inc

3,537
Mkt Cap
$332.12M
Volume
1.79M
52W High
$14.69
52W Low
$4.04
PE Ratio
19.10
NAGE Fundamentals
Price
$4.17
Prev Close
$4.19
Open
$4.23
50D MA
$4.72
Beta
1.35
Avg. Volume
646,411.40
EPS (Annual)
$0.2034
P/B
4.02
Rev/Employee
$1.11M
$481.40
Loading...
Loading...
News
all
press releases
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates
Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +16.67% and +5.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs
Niagen Bioscience reaffirms 2026 sales outlook after first-quarter revenue and profit rose alongside investments in injections and skincare.read more...
Benzinga·4d ago
News Placeholder
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026. First Quarter 2026 Financial Highlights Total net sales increased 3% to $31.5 million, including...
Business Wire·4d ago
News Placeholder
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of its...
Business Wire·6d ago
News Placeholder
Insider Decision Unfolding At Niagen Bioscience: Robert Fried Exercises Options, Resulting In $46K
read more...
Benzinga·12d ago
News Placeholder
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a new partnership with Olympia...
Business Wire·12d ago
News Placeholder
Notable Insider Move: Robert Fried Takes Part In Options Exercise At Niagen Bioscience, Resulting In $45K
read more...
Benzinga·13d ago
News Placeholder
Wall Street Zen Downgrades Niagen Bioscience (NASDAQ:NAGE) to Hold
Wall Street Zen lowered Niagen Bioscience from a "buy" rating to a "hold" rating in a research note on Saturday...
MarketBeat·16d ago
News Placeholder
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, May 6, 2026, at 4:30 p.m. ET to discuss its financial results for the first...
Business Wire·18d ago
<
1
2
...
>

Latest NAGE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.